Neoantigen Vaccines Pass the Immunogenicity Test

Gerald P Linette1, Beatriz M Carreno2

  • 1Department of Hematology/Oncology, Parker Institute for Cancer Immunotherapy and Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5157, USA.

Insights

Neoantigens, derived from tumor mutations, are non-self targets for cancer immunotherapy. Personalized vaccines targeting these neoantigens show promise for precision cancer therapy.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Neoantigens are derived from tumor-specific genomic alterations.
  • These neoantigens represent a novel class of targets for cancer immunotherapy.
  • Precision therapies are being developed based on individual tumor mutational profiles.

Purpose of the Study:

  • To highlight neoantigens as targets for cancer immunotherapy.
  • To discuss the potential of neoantigen-based vaccines for precision therapies.

Main Methods:

  • Review of recent reports on neoantigen vaccine platforms.
  • Analysis of tumor mutational profiles for neoantigen identification.

Main Results:

  • Neoantigens are authentic non-self antigens arising from tumor mutations.
  • Various vaccine platforms targeting neoantigens have been reported.
  • These platforms suggest a basis for customized precision therapies.

Conclusions:

  • Neoantigens represent a promising new class of targets in cancer immunotherapy.
  • Personalized neoantigen vaccines offer a path towards precision cancer medicine.